Drug recall · April 9, 2025
Duloxetine Delayed-Release Capsules recall
Why: CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Berkley Heights, NJ 07922, NDC 51991-747-10.
- Lots / codes
Lot 240909C, Exp Date 03/31/2027
- Quantity
- 14,863 bottles
- Company
- Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ
- Distribution
- Nationwide in the US
- Initiated
- March 26, 2025 · Voluntary: Firm initiated
- Classified
- April 1, 2025
- Reported
- April 9, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Duloxetine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.